DUBLIN--(BUSINESS WIRE)--The "DPP-IV Inhibitors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million.
The Global market is analyzed by the following Drugs:
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Others
The US market is further analysed in terms of sales by the following drug Segments:
- Sitagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
The report profiles 14 companies including many key and niche players such as:
- AstraZeneca Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
- Eli Lilly and Company (USA)
- Merck & Co, Inc. (USA)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Novartis AG (Switzerland)
-
Takeda Pharmaceutical Company Limited (Japan)
Key Topics Covered:
1. Introduction, Methodology & Product Definitions
2. Industry Overview
3. The Diabetes Epidemic
4. An Overview Of Drug Classes In Anti-Diabetic Drugs Category
5. A Review Of Select Approved DPP-IV Inhibitor Drugs
6. DPP-IV Inhibitors - An Overview Of The Drug Class
7. Competitive Landscape
8. Global Market Perspective
9. Regional Market Perspective
10. Company Profiles
Total Companies Profiled: 14 The United States (2)
- Japan (6)
-
Europe (3)
- Germany (1)
- The United Kingdom (1)
- Rest of Europe (1)
-
Asia-Pacific (Excluding Japan) (3)
For more information about this report visit https://www.researchandmarkets.com/research/dk699k/dppiv_inhibitors?w=4
